The Bone Biopsy Market Size was valued at USD 0.68 Billion in 2023. The Global Bone Biopsy industry is projected to grow from USD 0.72 Billion in 2024 to USD 1.11 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.49% during the forecast period (2024 - 2032).
Bone biopsy uses a needle and imaging guidance to eliminate a small sample of bone for examination under a microscope. Bone biopsies may be used to validate the diagnosis of a bone disorder, examine an abnormality, establish the cause of pain or infection, or differentiate bone tumors from other conditions.
The boost of the global bone biopsy market is driven by the factors such as the increasing prevalence of bone cancers and increasing acceptance of bone marrow biopsy for diagnosis and treatment of lymphoma and leukemia disease. In addition, improving healthcare infrastructure across emerging countries creates a lucrative opportunity for the market. However, stringent regulatory policies are likely to restrain the market growth.
COVID-19 Analysis:
The emergence of coronavirus negatively impacted various sectors across the globe. A few sections of the healthcare sector were also negatively impacted owing to production restrictions, cessation of clinical trials, and R&D activities. The increasing number of COVID-19-affected patients across the globe minimized the other treatment procedures. The life-threatening bone-related diseases were delayed or stopped due to the uncontrolled spread of coronavirus.
According to a survey conducted by the members of the ISOLS (International Society of Limb Salvage) and the EMSOS (European Musculo-Skeletal Oncology Society), nearly 20.7% of life-threatening sarcomas treatments were delayed. The pandemic outbreak disrupted the transportation and delivery of essential and non-essential products across the globe. The trade among countries declined thereafter. The transportation of goods was considered one of the ways of disease spread so countries across the globe implemented guidelines to adjourn trade until normalcy.
Growing demand for minimally invasive procedures is fuelling the growth of the global bone biopsy market. A minimally invasive procedure is the use of a variety of techniques to operate with less damage to the patient’s body. It has various benefits, such as fewer operative and post-operative major complications, less post-operative pain, shortened hospital stays, and faster recovery times. According to the WHO, in 2019, it was reported that around 235 million major surgeries are conducted every year across the globe.
Bone biopsy is a minimally invasive procedure that becomes the initial procedure of choice in most cases for obtaining bone samples. It offers multiple advantages over open surgical biopsy, including minimal soft tissue injury, maintenance of a bone structure, and a reduced need for general anesthesia. This results in an increasing preference for minimally invasive procedures by patients. This is driving the global bone biopsy market
Increasing acceptance of bone marrow biopsy for diagnosis and treatment of lymphoma and leukemia disease
The stringent regulatory policies for manufacturing and distributing medical devices in various regions are hampering the growth of the global bone biopsy market. For instance, the US Food & Drug Administration (FDA)’s Center for Devices and Radiological Health (CDRH) regulates the manufacturing, repackaging, relabelling, and/or importing of medical devices sold in the US. The basic regulatory requirements that manufacturers of medical devices distributed in the U.S. must comply with are established registration, medical device listing, premarket notification 510 (k), quality system regulations, medical device reporting, and others. Both domestic and foreign manufacturers of medical devices must register their establishments with the FDA. This is a restraining factor for the players involved in the global bone biopsy market.
Improving healthcare infrastructure across emerging countries is creating opportunities for the players involved in the bone biopsy market. The growth of the healthcare infrastructure enhances the development of advanced products for bone biopsy procedures. The players involved in the healthcare sector across emerging countries are heavily investing in technologies. For instance, in May 2022, Terumo India, the Indian arm of Terumo Corporation, signed a partnership agreement with US-based Argon Medical, the market leader in specialty medical products, including guide wires, IVC filters & retrievals, bone & soft tissue biopsy needles, and other products in India. It will help Terumo to offer advanced medical solutions. The geriatric population is increasing in emerging countries such as China and India. For instance, according to WHO, in 2019, there were 254 million older people aged 60 and over, and 176 million older people aged 65 and over in China. Geriatric people are more susceptible to chronic diseases such as cancer, which is also fuelling the demand for advanced bone biopsy products in the region.
Value Chain Analysis
The global bone biopsy market is showing positive movements in growth owing to the increasing cases of blood and marrow diseases and growing incidences of bone cancer across the globe. The value chain analysis for the market comprises four major components, which start with the R&D designing, manufacturing, distribution & sales, and post-sales review.
Bone biopsy needles and other products related to bone biopsy require extensive research and development to obtain accurate results. The scientific research and development of advanced and effective biopsy products have excelled in diagnosing bone marrow-related diseases among individuals. These products require years of investigation and product testing to get an efficient and accurate portfolio. R&D and designing of such products are focused on expanding their product range of new needles aimed at improving surgical procedures. In this process, the product strategies are ready, and the manufacturing process of the product commences. The manufacturing process begins with the assembling of raw materials and production of needles, and other products in-house or through third-party manufacturers. Distribution & sales is an essential part of any industry. The revenue of the bone biopsy market majorly depends on distribution and sales. This market consists of distribution & sales, which further includes intermediaries, direct selling, and others. A robust distribution network, strong customer base, and effective sales team drive the sales of bone biopsy consumables. As products in the market are developed for testing bone marrow problems, the development of abnormal cells and other bone problems are reviewed by government agencies, and their functions are monitored closely to minimize any side effects among the users. The products are also monitored to enhance the current functioning and eliminate the existing problems related to the side effects and other minor glitches.
Needle biopsies are majorly performed for the better assessment of bone cancer within an outpatient setting. The need for highly skilled operators to handle imaging modalities like CT scans and the lower technical complexities involved in this method are driving the demand for a needle biopsy to extract normal bone tissues for biopsy.
An open biopsy is a surgical procedure wherein an incision is made through the skin for exposing the tumor and allowing the tissue sample to be cut or scraped away. An open biopsy can be categorized as either incisional (the tumor capsule is intentionally violated as part of the procedure, and a portion of the mass or lesion is removed) or excisional (the entire tumor is removed).
Biopsy under MRI guidance is especially valuable for the localization of bone marrow lesions, lesions that cannot be visualized using CT, and viable tumors (after chemotherapy or radiation). In addition, MRI-guided bone biopsy is accurate, safe, a better alternative biopsy method, and is a good adjunctive technique for the localization of bone lesions for radiofrequency ablation or other interventional procedures.
Computed tomography (CT)-guided bone biopsy is a diagnostic procedure for obtaining a tissue sample with a high diagnostic yield and low complications. CT-guided biopsy combines a CT scan with a biopsy and uses images generated by a CT scanner (also called a cat scan) to accurately insert a needle into the suspect bone, allowing a sample to be removed for testing.
Bone biopsy is performed as an outpatient procedure in the hospital that normally takes less than 60 minutes and hospitals are one of the first contact points and the most trustable option for the patients. The growing incidence and prevalence of cancer, rising demand for minimally invasive procedures, and large geriatric patient population is driving the demand for bone biopsy.
The growing incidence of bone-related cancers coupled with the emergence of multiple detection approaches, including those involving advanced imaging techniques is driving the demand for bone biopsy in surgical centers. Bone biopsy is performed under the guidance of a variety of imaging modalities including computed tomography (CT) and magnetic resonance imaging (MRI). Benefits associated with the adoption of image-guidance biopsy in surgical centers such as avoidance of overnight hospital stay, earlier commencement of radiation therapy, cost & time saving, and biopsy of surgically inaccessible sites,
Other segments include diagnostic centers. Bone biopsies are conducted by diagnostic centers to facilitate definitive pathological diagnoses while minimizing complications, limiting potential tumor seeding, and avoiding interference with subsequent therapies. A rise in the demand for minimally invasive techniques which causes less pain is driving the segment growth.
North America
This is attributed to the increasing prevalence of bone disorders such as bone cancer, osteoporosis osteomyelitis, and others. Moreover, the presence of favorable reimbursement policies, well-developed healthcare infrastructure, and rapid adoption of advanced medical technologies in the region drive the regional market growth during the forecast period.
Asia-Pacific
Asia-Pacific is anticipated to register the highest growth rate over the forecast period. This is due to the factors such as improving healthcare infrastructure, government initiatives, and the increasing patient population suffering from bone cancer, bone Infection, osteoporosis, chronic kidney disease, and other bone disorders. For instance, according to the International Osteoporosis Foundation, by 2050, it is anticipated that Asia would account for more than 50% of all osteoporotic hip fractures worldwide.
Competitive Landscape
The global bone biopsy market is characterized by the presence of many global, regional, and local players. The high prevalence of bone cancer, increasing geriatric population, and favorable reimbursements are presenting lucrative opportunities to the industry players to maximize their share and gain a competitive edge in the market. In addition, the players are increasingly focusing on obtaining regulatory authorizations from government agencies for their products and emphasizing acquisitions and product launches to gain a substantial market share. For instance, in September 2018, Merit Medical Systems, Inc. (US) announced the expansion of its biopsy portfolio by the launch of new manual bone biopsy systems such as Madison and Huntington systems, Madison Mini, Westbrook, and Kensington bone biopsy systems for use in a wide variety of applications such as deep bone, upper spine & narrow access procedures among others. Such innovations are likely to increase North America’s bone biopsy market growth.
List of Key Companies Covered in this Report:
Recent Developments
Report Overview:
The report contains:
| Report Attribute/Metric | Details |
| Market Size | USD 1.11 Billion |
| CAGR | 5.49% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2018-2020 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Guided, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World |
| Key Vendors | Argon Medical (US), B. Braun Melsungen (Germany), Becton, Dickinson, and Company (US), Cardinal Health, Inc. (US), Mermaid Medical A / S (Denmark), Kimal PLC (UK), Stryker (US), Cook Group Incorporated (US), Remington Medical (Denmark), and Merit Medical Systems Inc. (US) |
| Key Market Opportunities | Improving healthcare infrastructure across emerging countries |
| Key Market Drivers | Increasing prevalence of bone cancers, growing demand for minimally invasive procedures, and increasing acceptance of bone marrow biopsy for diagnosis & treatment of lymphoma & leukemia disease |
Bone Biopsy Market Highlights:
Frequently Asked Questions (FAQ) :
Global bone biopsy market is expected to expand at 5.49% CAGR from 2024-2032.
bone biopsy market can touch USD 1.11 Billion by 2032.
Rising prevalence of bone cancer is the primary driver of the global bone biopsy market.
Recall of products and strict regulatory policies are factors expected to impede the global gastric bypass market growth.
The Americas is expected to dominate in the global bone biopsy market till 2032 due to high prevalence of bone cancer.
GENERAL ELECTRIC COMPANY, Cook, Kimal, Remington Medical, ARGON MEDICAL, BD, B. Braun Melsungen AG, Ranfac Corp., and MERMAID MEDICAL A/S are prominent players of the global bone biopsy market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
